In [78] it is concluded that cell-cycle progression in ER- breast cancer cells can be regulated by nuclear factor Nf-kB with inhibitory activity being a potentially novel therapeutic agent for ER- breast cancer patients. This evidence concerns the gene NFKB1 and breast cancer.